Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT).

Authors

Beth A. Hellerstedt

US Oncology Research, LLC, McKesson Specialty Health, The Woodlands, TX, and Texas Oncology, Central Austin Cancer Center, Austin, TX

Beth A. Hellerstedt , Gerald Edelman , Nicholas J. Vogelzang , Harriet M. Kluger , Christopher A. Yasenchak , Xiaodong Shen , David A. Ramies , Michael S. Gordon , Primo Lara Jr.

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2012 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Lung Cancer - Non-small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT00940225

Citation

J Clin Oncol 30, 2012 (suppl; abstr 7514)

DOI

10.1200/jco.2012.30.15_suppl.7514

Abstract #

7514

Poster Bd #

Abstract Disclosures

FEATURED

Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT).

Authors

Beth A. Hellerstedt

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Poster Details

Meeting

Session Type

Session Title

Track

Sub Track

Clinical Trial Registration Number

Citation

DOI

Abstract #

Poster Bd #

Similar Posters

Poster

Biomarker analysis of a phase II trial of cabozantinib and erlotinib in patients (pts) with EGFR-mutant NSCLC with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance: A California Cancer Consortium Phase II Trial (NCI 9303).

Poster

KRAS subset analysis from randomized phase II trials of erlotinib versus erlotinib plus sorafenib or pazopanib in refractory non-small cell lung cancer (NSCLC).

Poster

A phase III, randomized, double-blind, placebo-controlled study of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC) .

Poster

Bevacizumab (B) and erlotinib (E) as first-line therapy in metastatic non-squamous non-small cell lung cancer (NSCLC) followed by platinum-based chemotherapy (CT) at disease progression (PD): A multicenter phase II trial SAKK 19/05.